Prognostic Value of Long Non-coding RNA CCAT1 Expression in Patients with Cancer: A Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Jun 9

PMID 28594897

Citations 15

Authors

Deyao Shi

Fashuai Wu

Feng Gao

Xiangcheng Qing

Zengwu Shao

Affiliations

Soon will be listed here.

Abstract

Background: LncRNA CCAT1 is significantly overexpressed in various types of cancers, suggesting that it might be associated with prognosis and clinicopathological features in patients with cancer.

Methods: A comprehensive search was performed in Pubmed, Web of Science, OVID and CNKI databases. We also retrieved articles from other sources, such as retrieving from the reference lists of relevant articles. Eligible studies were included based on defined exclusion and inclusion criteria to perform a meta-analysis. STATA 14.0 was used to estimate pooled hazard ratios (HRs) with 95% confidence interval (95% CI), the heterogeneity among studies and publication bias to judge the prognostic value.

Results: A total of 1587 patients from 11 eligible studies were included in the meta-analysis. The results showed that high expression level of CCAT1 was significantly associated with shorter overall survival in cancer patients (HR 2.335, 95% CI:1.551-3.517); in the subgroup analysis, region (China or UK), sample size (more or less than 100), type of cancer (digestive or non-digestive disease) and paper quality (score more or less than 7) did not alter the association between CCAT1 expression and cancer prognosis but preoperative treatment did. And CCAT1 expression was an independent prognostic marker for overall survival in patients with cancer (pooled HR 2.195, 95%CI:1.316-3.664) using Cox multivariate analyses. The clinicopathological parameters analysis further showed that increased expression level of CCAT1 was correlated with tumor size, lymph node metastasis, TNM stage, distant metastasis, microvascular invasion and capsular formation in relevant cancers.

Conclusions: The meta-analysis results from present study suggested that increased expression level of CCAT1 was associated with poor prognosis and can serve as an independent biomarker. And the expression level of CCAT1 was associated with clinicopathological features in relevant cancers.

Citing Articles

LncRNAs in modulating cancer cell resistance to paclitaxel (PTX) therapy.

Alkhathami A, Pallathadka H, Shah S, Ganesan S, Sharma A, Devi S Med Oncol. 2024; 42(1):28.

PMID: 39671022 DOI: 10.1007/s12032-024-02577-1.

Expression of Concern: Prognostic value of long non-coding RNA CCAT1 expression in patients with cancer: A meta-analysis.

PLoS One. 2023; 18(4):e0284940.

PMID: 37079600 PMC: 10118116. DOI: 10.1371/journal.pone.0284940.

CCAT 1- A Pivotal Oncogenic Long Non-Coding RNA in Colorectal Cancer.

Liau X, Salvamani S, Gunasekaran B, Chellappan D, Rhodes A, Ulaganathan V Br J Biomed Sci. 2023; 80:11103.

PMID: 37025163 PMC: 10070472. DOI: 10.3389/bjbs.2023.11103.

Clinicopathological and prognostic value of long non-coding RNA CCAT1 expression in patients with digestive system cancer.

Yu Y, Xu Z, Ni H, Jin M, Dai C Oncol Lett. 2023; 25(2):73.

PMID: 36688111 PMC: 9843303. DOI: 10.3892/ol.2023.13659.

Non-coding RNAs regulation of macrophage polarization in cancer.

Mohapatra S, Pioppini C, Ozpolat B, Calin G Mol Cancer. 2021; 20(1):24.

PMID: 33522932 PMC: 7849140. DOI: 10.1186/s12943-021-01313-x.

References

Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y . LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis. 2014; 5:e1287. PMC: 4611722. DOI: 10.1038/cddis.2014.249. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Zhuang K, Wu Q, Jiang S, Yuan H, Huang S, Li H . CCAT1 promotes laryngeal squamous cell carcinoma cell proliferation and invasion. Am J Transl Res. 2016; 8(10):4338-4345. PMC: 5095326. View

Kam Y, Rubinstein A, Naik S, Djavsarov I, Halle D, Ariel I . Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT-PNA molecular beacons. Cancer Lett. 2013; 352(1):90-6. DOI: 10.1016/j.canlet.2013.02.014. View

Deng L, Yang S, Xu F, Zhang J . Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge. J Exp Clin Cancer Res. 2015; 34:18. PMC: 4339002. DOI: 10.1186/s13046-015-0136-7. View

Xin Y, Li Z, Shen J, Chan M, Wu W . CCAT1: a pivotal oncogenic long non-coding RNA in human cancers. Cell Prolif. 2016; 49(3):255-60. PMC: 6496795. DOI: 10.1111/cpr.12252. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Dong Y, Liang G, Yuan B, Yang C, Gao R, Zhou X . MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol. 2014; 36(3):1477-86. DOI: 10.1007/s13277-014-2631-4. View

Wang F, Xie C, Zhao W, Deng Z, Yang H, Fang Q . Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Clin Exp Med. 2015; 17(1):33-43. DOI: 10.1007/s10238-015-0395-9. View

10.

Cui Z, Chen Y, Xiao Z, Hu M, Lin Y, Chen Y . Long noncoding RNAs as auxiliary biomarkers for gastric cancer screening: A pooled analysis of individual studies. Oncotarget. 2016; 7(18):25791-800. PMC: 5041944. DOI: 10.18632/oncotarget.8268. View

11.

Ma M, Chu B, Zhang Y, Weng M, Qin Y, Gong W . Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis. 2015; 6:e1583. PMC: 4669740. DOI: 10.1038/cddis.2014.541. View

12.

Liu J, Shangguan Y . Long non-coding RNA CARLo-5 upregulation associates with poor prognosis in patients suffering gastric cancer. Eur Rev Med Pharmacol Sci. 2017; 21(3):530-534. View

13.

He X, Tan X, Wang X, Jin H, Liu L, Ma L . C-Myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasion. Tumour Biol. 2014; 35(12):12181-8. DOI: 10.1007/s13277-014-2526-4. View

14.

Liu F, Zhu P, Luo H, Zhang Y, Hao T, Xia G . Long noncoding RNA ANRIL: a potential novel prognostic marker in cancer: a meta-analysis. Minerva Med. 2016; 107(2):77-83. View

15.

Zhao X, Wei X, Zhao L, Shi L, Cheng J, Kang S . The rs6983267 SNP and long non-coding RNA CARLo-5 are associated with endometrial carcinoma. Environ Mol Mutagen. 2016; 57(7):508-15. DOI: 10.1002/em.22031. View

16.

Wright M, Bruford E . Naming 'junk': human non-protein coding RNA (ncRNA) gene nomenclature. Hum Genomics. 2011; 5(2):90-8. PMC: 3051107. DOI: 10.1186/1479-7364-5-2-90. View

17.

Xiang J, Yin Q, Chen T, Zhang Y, Zhang X, Wu Z . Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014; 24(5):513-31. PMC: 4011346. DOI: 10.1038/cr.2014.35. View

18.

Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F . Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J. 2014; 281(7):1750-8. DOI: 10.1111/febs.12737. View

19.

McCleland M, Mesh K, Lorenzana E, Chopra V, Segal E, Watanabe C . CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016; 126(2):639-52. PMC: 4731162. DOI: 10.1172/JCI83265. View

20.

Yarmishyn A, Kurochkin I . Long noncoding RNAs: a potential novel class of cancer biomarkers. Front Genet. 2015; 6:145. PMC: 4407501. DOI: 10.3389/fgene.2015.00145. View